Sutro Biopharma, Inc., was incorporated under the laws of the State of Delaware on April 21, 2003, formerly known as Fundamental Applied Biology, Inc. The Company is a clinical-stage oncology company developing site-specific and novel antibody-drug conjugates through its proprietary integrated cell-free protein synthesis platform XpressCF and site-specific binding platform XpressCF +. The company's goal is to design and develop treatments that use the most relevant and effective models, including ADCs, bispecific ADCs, immunostimulating ADCs or iADCs, bi-conjugate ADCs or ADC2, and cytokine derivatives. The Company's most advanced product candidate is STRO-002, or luveltamab tazevibulin, or luvelta, an ADC targeting folate receptor-α, or FolRα, for cancer patients expressing FolRα, including ovarian cancer. 

Expected P&L on Expiry

Key Stats

Pricing Model

About STRO20260220C12.5